Back to Search
Start Over
Antiangiogenic therapies in urogenital malignancies: Fiction or fact?
- Source :
- Memo
- Publication Year :
- 2017
-
Abstract
- Summary The use of antiangiogenic agents in cancer therapy has become an attractive target in oncological research. However, concerning the uro-oncological field, current guidelines only recommend the use of antiangiogenic agents in metastatic renal cell cancer. Yet in recent years, several approaches for sequential treatment with angiogenesis inhibitors in other urogenital malignancies apart from renal cell cancer are ongoing. Thus, the present review article aims to provide an overview about clinical studies with antiangiogenic agents in prostate-, bladder-, testicular-, as well as penile cancer patients. For this, a literature search was conducted using Medline; moreover we performed a systematic review of data presented at this year’s important urooncological meetings. Preliminary data revealed that there are several promising studies ongoing in prostate-, bladder-, testicular-, as well as penile cancer; however, larger studies should be conducted to optimize the use of antiangiogenic agents in clinical practice.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
Angiogenesis
MEDLINE
Review
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Testicular cancer
Prostate
Internal medicine
medicine
Urothelial cancer
Penile cancer
Genitourinary system
business.industry
Hematology
Antiangiogenic therapeutics
medicine.disease
Review article
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
business
Subjects
Details
- ISSN :
- 18655041
- Volume :
- 10
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Memo
- Accession number :
- edsair.doi.dedup.....f2e772bb508a0a241585151b04a4a435